BTG Interventional Oncology is transforming cancer care with smarter solutions

BTG Interventional Oncology is transforming the way cancer is treated with our wide-ranging solutions of minimally-invasive, highly targeted cancer therapies.

Explore io

show favorites
ICEfx CIRSE launch

ICEfx™ launches at CIRSE 2018!

News
25 Aug
Canada

Health Canada approves radiopaque bead for HCC, CRC liver metastases

BTG International Canada Inc. announced it received approval for its drug-eluding device, the DC Bead LUMI, from Health Canada. The bead is the...
Update
London, UK

BTG ANNOUNCES GLOBAL LAUNCH OF THE ICEfx™ CRYOABLATION SYSTEM

September 20, 2018: BTG plc (LSE: BTG), a global specialist healthcare company, today announced the global launch of the ICEfx Cryoablation System. ICEfx, an evolution of the existing Visual ICE system, offers predictable, reliable performance with seamless therapy delivery and exceptional ease of technical operation. This compact and powerful console is designed for interventional radiologists who want to offer their patients state-of-the-art, minimally invasive treatment options.
Product
DC Bead LUMI™

DC Bead LUMI™

With DC Bead LUMI™, you are empowered to see the location of the beads during and after LUMI-TACE
Video

Immunotherapy in combination with Cryoablation, TACE or SIRT

BTG ECIO 2018 Symposium – ON DEMAND
Events
07-08 Dec 18

GEST ASIA 2018

Hong Kong, Hong Kong S.A.R.
Events
01 Nov 18

Synergy: A Multidisciplanary Approach to Interventional Oncology

Miami Beach, FL, United States
Video

The Future of SIRT

Evolving Liver Cancer Strategies
BTG ECIO 2018 Symposium – ON DEMAND
 
Update
London

BTG plc acquires Novate Medical Ltd.

BTG plc (LSE: BTG), the global specialist healthcare company, today announces it has acquired Novate Medical Ltd. (“Novate”), a medical device company focused on the prevention of pulmonary embolism (PE) in patients at high risk of venous thromboembolic events.
News
12 Apr
Indiana

New procedure uses tiny beads to blast away liver cancer

Treating cancer that began in the liver or has spread to the liver can often involve months of chemotherapy and painful radiation treatments. But...
BTG@CIRSE 2018

BTG@CIRSE 2018

We are gearing up for #CIRSE2018 in September, It's going to be a great meeting!
Follow @BTGIO to see more!
Let's Stay In Touch!

Let’s stay in touch!

Please visit our preference centre to update your email settings
News
06 May
London, UK

BTG snaps up cryogenic oncology specialist Galil for £58.3M

BTG Group is buying a US company that develops medical devices which kill tumours by freezing them, as it looks to further boost its presence in...
Update
London, UK

Institutional Decision to Adopt Y90 TARE with TheraSphere® as first-line treatment for HCC

Based on experience with 1000 patients over 15 years, the largest single-centre, prospective centre cohort of patients with HCC treated with Y90 glass microspheres
Video

The Future of Focal Cryotherapy in Prostate Cancer – Highlights from Amsterdam

Events
14-16 Nov 18

BSIR - British Society of Interventional Radiology

Bournemouth, United Kingdom
Video

TheraSphere® vial flushing

Update
London, UK

BTG plc acquires Roxwood Medical

London, UK, 5 October 2017: BTG plc (LSE: BTG), the global specialist healthcare company, today announces it has acquired Roxwood Medical (“Roxwood”), an innovative provider of advanced cardiovascular specialty catheters used in the treatment of patients with severe coronary and peripheral artery disease.
News
07 Jan
US and Canada

Cutting Edge Treatment Improves Prospects For Liver Cancer Patients

RESEARCH ADVANCES In October, iconic buildings throughout the United Kingdom were bathed in pink light. NFL players wore pink on their shoes during...
CRYOABLATION

CRYOABLATION

Breaking Boundaries with Ice
BTG @CIRSE 2017

BTG @CIRSE 2017

Update
London, UK

Mirada Medical signs three-year software development agreement with BTG

Mirada Medical Ltd, a global medical imaging software company, has signed a three-year master service agreement with BTG plc (LSE: BTG), a global specialist healthcare company. The agreement covers multiple software development projects to support BTG’s portfolio of interventional medicine products.
Video

BTG@CIRSE 2017 - hands-on sessions

Video

DC Bead LUMI™

Building on the established clinical performance of DC Bead®, DC Bead LUMI™ provides real-time visible confirmation of bead location during embolisation.
Update

BTG and SIO expand Immuno-Oncology / Interventional Oncology grant programme

BTG plc (LSE: BTG), a global specialist healthcare company, and the Society of Interventional Oncology (SIO), an international organisation working to nurture and support interventional oncology worldwide, have expanded their commitment to the Immuno-Oncology / Interventional Oncology research grant programme, by announcing a second round of funding available to investigators.
Twitter No2

 @BTGIO

Twitter No1

 @BTGIO

Video

TheraSphere®

TheraSphere® yttrium-90 glass microspheres deliver a targeted radiation dose to the tumour whilst minimising exposure to healthy tissue with mild to...
@BTGIO

 @BTGIO

The Interventional Initiative

The Interventional Initiative

SIR 2017
LOAD MORE CONTENT

Explore io solution

ENGAGE WITH BTGIO

Our whole world is interventional oncology and if yours is too we want to hear from you Get in touch
Your name is
   
Your company is
   
Your email is
   
Your question is
image image image image